Selective inhibitors of cardiac ADPR cyclase as novel anti-arrhythmic compounds

ADP-ribosyl cyclases (ADPRCs) catalyse the conversion of nicotinamide adenine dinucleotide to cyclic adenosine diphosphoribose (cADPR) which is a second messenger involved in Ca 2+ mobilisation from intracellular stores. Via its interaction with the ryanodine receptor Ca 2+ channel in the heart, cAD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Naunyn-Schmiedeberg's archives of pharmacology 2012-07, Vol.385 (7), p.717-727
Hauptverfasser:	Kannt, Aimo, Sicka, Kerstin, Kroll, Katja, Kadereit, Dieter, Gögelein, Heinz
Format:	Artikel
Sprache:	eng
Schlagworte:	ADP-ribosyl Cyclase - antagonists & inhibitors ADP-ribosyl Cyclase - metabolism Animals Anti-Arrhythmia Agents - pharmacology Biomedical and Life Sciences Biomedicine Calcium - physiology Enzyme Inhibitors - pharmacology Guinea Pigs Heart - physiology Heterocyclic Compounds, 3-Ring - pharmacology Heterocyclic Compounds, 4 or More Rings - pharmacology In Vitro Techniques Myocardium - enzymology Myocytes, Cardiac - drug effects Myocytes, Cardiac - physiology Neurosciences Original Original Article Papillary Muscles - drug effects Papillary Muscles - physiology Pharmacology/Toxicology Rats Sarcoplasmic Reticulum - drug effects Sarcoplasmic Reticulum - physiology Swine Ventricular Fibrillation - drug therapy Ventricular Fibrillation - physiopathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!